OpGen Announces Closing of $10 Million Private Placement

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
OpGen Announces Closing of $10 Million Private Placement

GAITHERSBURG, Md., May 20, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN ), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the first closing of a private placement financing raising gross proceeds of $10.4 million.  The Company will use the net proceeds, after payment of offering expenses, to support the sales and marketing and continued research and development of the Company’s rapid diagnostic and Acuitas Lighthouse™ bioinformatics products and services, and for general corporate purposes.

Lead investors in the financing included Merck Global Health Innovation Fund (Merck GHI) and Sabby Management, LLC.   OpGen management and certain directors also participated in the financing. Cowen and Company acted as sole lead placement agent, Leerink Partners LLC acted as financial advisor, and Maxim Group LLC acted as co-placement agent to the Company for the financing.

“We are pleased that a prominent institutional healthcare investor has recognized our potential with its investment,” said Evan Jones, OpGen chairman and chief executive officer. “We view participation in our financing as validation of our efforts to fight infectious disease and combat and contain multidrug-resistant organisms, a growing healthcare emergency.”

The financing consisted of units sold at a price of $1.14375 per unit. Each unit consists of either one share of common stock, par value $0.01 per share, or one share of non-voting, convertible preferred stock, and one warrant to acquire 0.75 of one share of common stock. The Company issued an aggregate of 6,744,128 shares of common stock, 2,309,428 shares of preferred stock, and warrants to purchase 6,790,169 shares of common stock.   The warrants are exercisable beginning 90 days after the closing date, have an exercise price of $1.3125 per share of common stock and may be exercised for five years.   

The private placement will be closed in two transactions, the second closing is expected to occur in mid-June 2016, following distribution by the company of an information statement to its stockholders describing the transaction.

The securities offered in this private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws, and accordingly may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in this private placement and the shares of common stock issuable upon the exercise of the warrants and the conversion of the preferred stock issued in this private placement.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be by means of a prospectus.

About OpGen OpGen, Inc. is developing and deploying precision medicine tools to combat infectious disease in global healthcare settings, helping physicians improve patient outcomes by providing more rapid information about life-threatening infections and decreasing the spread of infections caused by multidrug-resistant microorganisms.  OpGen offers a full portfolio of in vitro diagnostic products and clinical laboratory services that employ state-of-the-art molecular diagnostics and bioinformatics.  Its QuickFISH® products are a suite of FDA-cleared and CE-marked diagnostics used to rapidly detect pathogens in positive blood cultures.  Clinical laboratory services utilize the Acuitas® products, including the MDRO Gene Test, the Resistome Test, microbial Whole Genome Sequence Analysis and Acuitas Lighthouse™ bioinformatics system designed to detect, type, track and trend antibiotic resistant organisms in real-time.  Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn . 

OpGen Forward-Looking Statements  This press release includes statements relating to the expected proceeds from the Company’s private placement and the Company's products and services. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, risks related to the capital markets generally and the satisfaction of the closing conditions to the offering, the rate of adoption of our products and services by hospitals, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission (“SEC”), including our Quarterly Report on Form 10-Q for the three months ended March 31, 2016, filed with the SEC on May 16, 2016. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts:

OpGen Michael Farmer Director, Marketing (240) 813-1284 mfarmer@opgen.com   InvestorRelations@opgen.com                   Investor Relations LHA Kim Sutton Golodetz (212) 838-3777 kgolodetz@lhai.com   or Bruce Voss (310) 691-7100 bvoss@lhai.com  

OpGen media MacDougall Biomedical Communications Cammy Duong 781-591-3443 cduong@macbiocom.com  

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 255

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 339

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 215

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 169

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 266

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 209

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 156

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 232

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

Runway Growth Finance Highlights Portfolio Performance 2025

Updated Category News Views 258

Overview of Runway Growth Finance Corp. Runway Growth Finance Corp. (NASDAQ: RWAY) is paving its path as a leading provider of flexible capital solutions aimed at late- and growth-stage companies. Their mission is to present an alternative for businesses looking to raise equity, and they have recently shared their quarterly operational update for the period ending June...

Continue Reading
Market Anticipation: Fed's Expected Interest Rate Moves

Updated Category News Views 113

Federal Reserve's Interest Rate Decisions in Focus The upcoming meeting of the Federal Reserve is drawing considerable interest from economists and investors. Everyone is keenly awaiting the outcome regarding potential interest rate cuts as market conditions continue to shift. With the discussion around monetary policy heating up, there’s a range of opinions on how...

Continue Reading
Argon Medical Makes Progress with Innovative PE Treatment Trial

Updated Category News Views 361

Argon Medical Devices Launches CLEAN-PE Study for Pulmonary Embolism Argon Medical Devices is making significant strides in the medical field with its recent announcement of the first patient enrollment in the CLEAN-PE study. This prospective and multicenter study is designed to test the Cleaner™ Pro Thrombectomy System, which aims to effectively address pulmonary...

Continue Reading
Citi Adjusts PBF Energy Stock Target as Market Challenges Emerge

Updated Category News Views 53

Citi Revises Price Target for PBF Energy Recently, Citi has made a noteworthy adjustment to the price target for PBF Energy (NYSE: PBF), reducing it from $48.00 to $37.00. This update follows an extensive review of the refining company's financial model against the backdrop of fluctuating commodity prices. Despite this shift, Citi maintains a Neutral rating on the stock,...

Continue Reading
Clip Total 3: Revolutionizing Mobile Payments for Businesses

Updated Category News Views 174

Introducing Clip Total 3: A Game-Changer for Businesses Clip, the prominent digital commerce platform in Mexico, has recently launched the Clip Total 3, marking a significant leap in mobile point-of-sale technology for businesses across various sectors. This next-generation device is designed not only for payment acceptance but also for comprehensive business management....

Continue Reading